{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:06:15Z","timestamp":1794405975561,"version":"4.9.0"},"publisher-location":"Berlin, Heidelberg","reference-count":43,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642814907","type":"print"},{"value":"9783642814884","type":"electronic"}],"license":[{"start":{"date-parts":[[1980,1,1]],"date-time":"1980-01-01T00:00:00Z","timestamp":315532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1980,1,1]],"date-time":"1980-01-01T00:00:00Z","timestamp":315532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1980]]},"DOI":"10.1007\/978-3-642-81488-4_14","type":"book-chapter","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T00:37:49Z","timestamp":1323218269000},"page":"98-106","source":"Crossref","is-referenced-by-count":9,"title":["The Epipodophyllotoxin Derivatives VM-26 and VP-16-213, 1976\u20131979, a Review"],"prefix":"10.1007","author":[{"given":"N. I.","family":"Nissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dombernowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. H.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"14_CR1","first-page":"1681","volume":"60","author":"DL Ahmann","year":"1976","unstructured":"Ahmann DL, Bisel HF, Edmonson JH, Hahn RG, O\u2019Connell MJ, Frytak S (1976) Phase II study of VP16-213 versus dihydrogalactitol in patients with metastatic malignant melanoma. Cancer Treat Rep 60:1681\u20131682","journal-title":"Cancer Treat Rep"},{"key":"14_CR2","first-page":"22","volume":"18","author":"LM Allen","year":"1977","unstructured":"Allen LM, Shirley M (1977) Mechanism of cellular transport of two epipodophyllotoxin glucopyranoside derivatives, VM 26 and VP 16. Proc Am Assoc Cancer Res 18:22","journal-title":"Proc Am Assoc Cancer Res"},{"key":"14_CR3","first-page":"125","volume":"19","author":"LM Allen","year":"1978","unstructured":"Allen, LM (1978) Cellular pharmacokinetics of two epipodophyllotoxin glucopyranoside derivatives, VM 26 and VP 16: Uptake in the presence and absence of human serum albumin. Proc Am Assoc Cancer Res 19:125","journal-title":"Proc Am Assoc Cancer Res"},{"key":"14_CR4","first-page":"445","volume":"62","author":"RE Bellet","year":"1978","unstructured":"Bellet RE, Catalano RB, Mastrangelo MJ, Berd D, Koons LS (1978) Phase II trial of VM 26 in patients with metastatic malignant melanoma. Cancer Treat Rep 62:445\u2013447","journal-title":"Cancer Treat Rep"},{"key":"14_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/ajh.2830050305","volume":"5","author":"RA Bender","year":"1978","unstructured":"Bender RA, Anderson T, Fisher RI, Yong RC (1978) Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma. Am J Hematol 5:203\u2013209","journal-title":"Am J Hematol"},{"key":"14_CR6","first-page":"407","volume":"19","author":"VK Bhuchar","year":"1978","unstructured":"Bhuchar VK, Boyle LE, Lanzotti VJ (1978) VM 26 in non-oat cell bronchogenic carcinoma. Proc Am Soc Clin Oncol 19:407","journal-title":"Proc Am Soc Clin Oncol"},{"key":"14_CR7","first-page":"373","volume":"19","author":"WA Bleyer","year":"1978","unstructured":"Bleyer WA, Chard RL, Kriwit W, Hammond D (1978) Epipodophyllotoksin therapy of childhood neoplasia: A comparative phase 2 analysis of VM 26 and VP 16-213. Proc Am Soc Clin Oncol 19:373","journal-title":"Proc Am Soc Clin Oncol"},{"key":"14_CR8","first-page":"1377","volume":"60","author":"KW Brunner","year":"1976","unstructured":"Brunner KW, Sonntag RW, Ryssel HJ, Cavalli F (1976) Comparison of the biologic activity of VP 16-213 given iv and orally in capsules or drink ampules. Cancer Treat Rep 60:1377\u20131379","journal-title":"Cancer Treat Rep"},{"key":"14_CR9","first-page":"473","volume":"62","author":"F Cavalli","year":"1978","unstructured":"Cavalli F, Sonntag RW, Jungi F, Senn HJ, Brunner KW (1978) VP 16-213 monotherapy for remission induction of small cell lung cancer: A randomized trial using three dosage schedules. Cancer Treat Rep 62:473\u2013475","journal-title":"Cancer Treat Rep"},{"key":"14_CR10","first-page":"801","volume":"62","author":"JW Cecil","year":"1978","unstructured":"Cecil JW, Quagliana JM, Coltman CA, Al-Sarraf M, Thigpen T, Groppe CW (1978) Evaluation of VP 16-213 in malignant lymphoma and melanoma. Cancer Treat Rep 62:801\u2013803","journal-title":"Cancer Treat Rep"},{"key":"14_CR11","first-page":"354","volume":"18","author":"RL Chard","year":"1977","unstructured":"Chard RL, Hammond D (1977) 4\u2019-Demethylepipodophyllotoxin-\/?-D-ethylidene glucoside (VP 16-213) phase II study for refractory acute leukemias of childhood. Proc Am Soc Clin Oncol 18:354","journal-title":"Proc Am Soc Clin Oncol"},{"key":"14_CR12","first-page":"7","volume":"63","author":"DF Chiuten","year":"1979","unstructured":"Chiuten DF, Bennett JM, Creech RH, Glick J, Falkson G, Brodovsky HS, Begg CB, Muggia FM, Carbone PP (1979) VM 26, a new anticancer drug with effectiveness in malignant lymphoma: An Eastern Cooperative Oncology Group study. Cancer Treat Rep 63:7\u201311","journal-title":"Cancer Treat Rep"},{"key":"14_CR13","first-page":"489","volume":"61","author":"MH Cohen","year":"1977","unstructured":"Cohen MH, Broder LE, Fossieck BE, Ihde DC, Minna JD (1977) Phase II clinical trial of weekly administration of VP 16-213 in small cell bronchogenic carcinoma. Cancer Treat Rep 61:489\u2013490","journal-title":"Cancer Treat Rep"},{"key":"14_CR14","first-page":"71","volume":"56","author":"P Dombernowsky","year":"1972","unstructured":"Dombernowsky P, Nissen NI, Larsen V (1972) Clinical investigation of a new podophyllin derivative, VM 26, in patients with malignant lymphomas and solid tumors. Cancer Chemother Rep 56:71\u201382","journal-title":"Cancer Chemother Rep"},{"key":"14_CR15","first-page":"1295","volume":"60","author":"B Drewinko","year":"1976","unstructured":"Drewinko B, Barlogie B (1976) Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP 16-213. Cancer Treat Rep 60:1295\u20131306","journal-title":"Cancer Treat Rep"},{"key":"14_CR16","first-page":"949","volume":"60","author":"RT Eagan","year":"1976","unstructured":"Eagan RT, Carr DT, Frytak S, Rubin J, Lee RE (1976) VP 16-213 versus polychemotherapy in patients with advanced small cell lung cancer. Cancer Treat Rep 60:949\u2013951","journal-title":"Cancer Treat Rep"},{"key":"14_CR17","first-page":"843","volume":"62","author":"RT Eagan","year":"1978","unstructured":"Eagan RT, Ingle JN, Creagan ET, Frytak S, Kvols LK, Rubin J, McMahon RT (1978) VP 16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 62:843\u2013844","journal-title":"Cancer Treat Rep"},{"key":"14_CR18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/bmj.2.5816.744","volume":"2","author":"European Organization for Research on the Treatment of Cancer, Cooperative Group for Leukaemias and Haematosarcomas","year":"1972","unstructured":"European Organization for Research on the Treatment of Cancer, Cooperative Group for Leukaemias and Haematosarcomas (1972) Clinical screening of epipodophyllotoxin VM 26 in malignant lymphomas and solid tumors. Br Med J 2:744\u2013748","journal-title":"Br Med J"},{"key":"14_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/bmj.3.5873.199","volume":"3","author":"European Organization for Research on the Treatment of Cancer, Clinical Screening Group","year":"1973","unstructured":"European Organization for Research on the Treatment of Cancer, Clinical Screening Group (1973) Epipodophyllotoxin VP 16-213 in treatment of acute leukaemias, haematosarcomas and solid tumors. Br Med J 3:199\u2013202","journal-title":"Br Med J"},{"key":"14_CR20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/1097-0142(197504)35:4<1141::AID-CNCR2820350418>3.0.CO;2-3","volume":"35","author":"G Falkson","year":"1975","unstructured":"Falkson G, Dyk J J van, Eden EB van, Merwe AM van de, Berg J A van den, Falkson HC (1975) A clinical trial of the oral form of 4\u2019demethyl-epipodophyllotoxin-\u03b2-D-ethylidene glucoside, VP 16-213. Cancer 35:1141\u20131144","journal-title":"Cancer"},{"key":"14_CR21","first-page":"2998","volume":"37","author":"A Grieder","year":"1977","unstructured":"Grieder A, Maurer R, St\u00e4helin H (1977) Comparative study of early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures. Cancer Res 37:2998\u20133005","journal-title":"Cancer Res"},{"key":"14_CR22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/1097-0142(197708)40:2<633::AID-CNCR2820400207>3.0.CO;2-O","volume":"40","author":"M Hansen","year":"1977","unstructured":"Hansen M, Hirsch F, Dombernowsky P, Hansen HH (1977) Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP 16-213 (NSC 141540, 4\u2019-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-\u03b2-D-glucopyranoside). Cancer 40:633\u2013637","journal-title":"Cancer"},{"key":"14_CR23","first-page":"289","volume":"20","author":"P Jacobs","year":"1979","unstructured":"Jacobs P, King H, Cassidy F, Dent D (1979) The treatment of diffuse lymphocytic lymphoma (large cell) with VP 16-213. Proc Am Assoc Cancer Res 20:289","journal-title":"Proc Am Assoc Cancer Res"},{"key":"14_CR24","first-page":"483","volume":"49","author":"P Jacobs","year":"1975","unstructured":"Jacobs P, King HS, Sealy GRH (1975) Epipodophyllotoxin (VP 16-213) in the treatment of diffuse histiocytic lymphoma. S Afr Med J 49:483\u2013485","journal-title":"S Afr Med J"},{"key":"14_CR25","first-page":"737","volume":"59","author":"WF Jungi","year":"1975","unstructured":"Jungi WF, Senn YU (1975) Clinical study of the new podophyllotoxin derivative, 4\u2019-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-\u03b2-D-glucopyranoside) (NSC-141540; VP 16-213), in solid tumors in man. Cancer Chemother Rep 59:737\u2013742","journal-title":"Cancer Chemother Rep"},{"key":"14_CR26","first-page":"485","volume":"63","author":"ME Lau","year":"1979","unstructured":"Lau ME, Hansen HH, Nissen NI, Pedersen H (1979) Phase I trial of a new form of an oral administration of VP 16-213. Cancer Treat Rep 63:485\u2013487","journal-title":"Cancer Treat Rep"},{"key":"14_CR27","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1021\/bi00670a003","volume":"15","author":"JD Loike","year":"1976","unstructured":"Loike JD, Horwitz SB (1976) Effects of podophyllotoxin and VP 16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry 15:5435\u20135443","journal-title":"Biochemistry"},{"key":"14_CR28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/1097-0142(197410)34:4<985::AID-CNCR2820340402>3.0.CO;2-U","volume":"34","author":"G Math\u00e9","year":"1974","unstructured":"Math\u00e9 G, Schwarzenberg L, Pouillart P, Oldham R, Weiner R, Jasmin C, Rosenfeld C, Hayat M, Misset JL, Musset M, Schneider M, Amiel JL, De Vassal F (1974) Two epipodophyllotoxin derivatives, VM 26 and VP 16-213, in the treatment of leukemias, hematosarcomas, and lymphomas. Cancer 34:985\u2013992","journal-title":"Cancer"},{"key":"14_CR29","first-page":"943","volume":"60","author":"NI Nissen","year":"1976","unstructured":"Nissen NI, Dombernowsky P, Hansen HH, Larsen V (1976) Phase I clinical trial of an oral solution of VP 16-213. Cancer Treat Rep 60:943\u2013945","journal-title":"Cancer Treat Rep"},{"key":"14_CR30","first-page":"1027","volume":"59","author":"NI Nissen","year":"1975","unstructured":"Nissen NI, Hansen HH, Pedersen H, Stroyer I, Dombernowsky P, Hessellund M (1975) Clinical trial of the oral form of a new podophyllotoxin derivative, VP 16-213 (NSC-141540), in patients with advanced neoplastic disease. Cancer Chemother Rep 59:1027\u20131029","journal-title":"Cancer Chemother Rep"},{"key":"14_CR31","first-page":"769","volume":"56","author":"NI Nissen","year":"1972","unstructured":"Nissen NI, Larsen V, Pedersen H, Thomsen K (1972) Phase I clinical trial of a new anti- tumor agent, 4\u2019demethylepipodophyllotoxin 9-(4,6-0-ethylidene-\u03b2-D-glucopyranoside) (NSC-141540; VP 16-213). Cancer Chemother Rep 56:769\u2013777","journal-title":"Cancer Chemother Rep"},{"key":"14_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/1097-0142(19800115)45:2<232::AID-CNCR2820450206>3.0.CO;2-F","volume":"45","author":"NI Nissen","year":"1980","unstructured":"Nissen NI, Pajak TF, Leone LA, Bloomfield C, Kennedy BJ, Ellison RR, Silver RT, Jones B, Holland JF, Falkson FK, Lee S (1980) Clinical trial of VP 16-213 (NSC 141540) iv twice weekly in advanced neoplastic disease. A study by the Cancer and Leukemia Group B. Cancer 45:232\u2013235","journal-title":"Cancer"},{"key":"14_CR33","first-page":"1243","volume":"61","author":"G Rivera","year":"1977","unstructured":"Rivera G, Green A, Hayes A, Avery T, Pratt C (1977) Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma. Cancer Treat Rep 61:1243\u20131248","journal-title":"Cancer Treat Rep"},{"key":"14_CR34","first-page":"265","volume":"60","author":"JG Rosenstock","year":"1976","unstructured":"Rosenstock JG, Donaldson MH (1976) Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia. Cancer Treat Rep 60:265\u2013267","journal-title":"Cancer Treat Rep"},{"key":"14_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/1097-0142(197707)40:1<334::AID-CNCR2820400147>3.0.CO;2-X","volume":"40","author":"M Rozencweig","year":"1977","unstructured":"Rozencweig M, Von Hoff DD, Henney JE, Muggia FM (1977) VM 26 and VP 16-213: A comparative analysis. Cancer 40:334\u2013342","journal-title":"Cancer"},{"key":"14_CR36","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/0014-2964(78)90124-X","volume":"15","author":"MK Samson","year":"1978","unstructured":"Samson MK, Baker LH, Talley RW, Fraile RJ (1978) VM 26 (NSC-122819): A clinical study in advanced cancer of the lung and ovary. Eur J Cancer 15:1395\u20131399","journal-title":"Eur J Cancer"},{"key":"14_CR37","first-page":"346","volume":"19","author":"JJ Schulz","year":"1978","unstructured":"Schulz JJ, Spremulli EN, Wampler GL (1978) Phase II trial of 4\u2019-demethylepipodophyl- lotoxin-9-(4,6-0-2-thenylidene-^-D-glucopyranoside) (VM-26). Proc Am Soc Clin Oncol 19:346","journal-title":"Proc Am Soc Clin Oncol"},{"key":"14_CR38","first-page":"190","volume":"20","author":"R Slayton","year":"1979","unstructured":"Slayton R, Petty W, Blessing J (1979) Phase II trial of VP-16 in treatment of advanced ovarian adenocarcinoma. Proc Am Assoc Cancer Res 20:190","journal-title":"Proc Am Assoc Cancer Res"},{"key":"14_CR39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/pgmj.52.604.66","volume":"52","author":"IE Smith","year":"1976","unstructured":"Smith IE, Gerken ME, Clink HM, McElwain TJ (1976) VP 16-213 in acute myelogenous leukaemia. Postgrad Med J 52:66\u201370","journal-title":"Postgrad Med J"},{"key":"14_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0014-2964(74)90058-9","volume":"10","author":"RW Sonntag","year":"1974","unstructured":"Sonntag RW, Senn HJ, Nagel G, Giger K, Alberto P (1974) Experience with 4\u2019-demethylepipodophyllotoxin 9-(4,6-0-2-thenylidene-beta-D-glucopyranoside); VM 26; NSC-122819 in the treatment of malignant lymphosis. Eur J Cancer 10:93\u201398","journal-title":"Eur J Cancer"},{"key":"14_CR41","first-page":"155","volume":"63","author":"MP Sullivan","year":"1978","unstructured":"Sullivan MP, Eys J van, Herson J, Starling KA, Ragab A, Sexhauer C (1978) Nonresponsiveness of brain tumors to VM-26 therapy in children. Cancer Treat Rep 63:155\u2013156","journal-title":"Cancer Treat Rep"},{"key":"14_CR42","first-page":"79","volume":"11","author":"G Trempe","year":"1970","unstructured":"Trempe G, Sykes M, Young C, Krakoff I (1970) Phase I trial of the podophyllotoxin derivative VM 26. Proc Am Assoc Cancer Res 11:79","journal-title":"Proc Am Assoc Cancer Res"},{"key":"14_CR43","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/1097-0142(197805)41:5<1710::AID-CNCR2820410509>3.0.CO;2-M","volume":"41","author":"RD Tucker","year":"1978","unstructured":"Tucker RD, Ferguson A, Wyk C van, Sealy R, Hewitson R, Levin W (1978) Chemotherapy of small cell carcinoma of the lung with VP 16-213. Cancer 41:1710\u20131714","journal-title":"Cancer"}],"container-title":["Recent Results in Cancer Research","Cancer Chemo- and Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-81488-4_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T07:03:51Z","timestamp":1676099031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-81488-4_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1980]]},"ISBN":["9783642814907","9783642814884"],"references-count":43,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-81488-4_14","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-3-642-81488-4","asserted-by":"object"}]},"ISSN":["0080-0015"],"issn-type":[{"value":"0080-0015","type":"print"}],"subject":[],"published":{"date-parts":[[1980]]}}}